Naltrexone/Bupropion

Overview

Naltrexone/Bupropion is a fixed-dose combination of two well-characterised molecules: naltrexone (an opioid receptor antagonist) and bupropion (a norepinephrine-dopamine reuptake inhibitor). Marketed as Mysimba/Contrave, this combination exploits the convergence of opioid and dopaminergic reward pathways in appetite regulation. The compounds individually have modest effects on body weight, but their combination produces synergistic appetite suppression through complementary mechanisms in the hypothalamic melanocortin system and mesolimbic reward circuits.

Mechanism of Action

Bupropion stimulates hypothalamic POMC neurons to release α-MSH, which activates MC4R to suppress appetite. However, POMC neurons simultaneously release β-endorphin, which acts as an autoinhibitory feedback via mu-opioid receptors on the same neurons — limiting bupropion's anorectic effect. Naltrexone blocks this mu-opioid autoinhibition, sustaining POMC neuron firing and prolonging α-MSH release. In the mesolimbic reward system, bupropion reduces the reinforcing value of food via dopamine/norepinephrine reuptake inhibition, while naltrexone attenuates hedonic (pleasure-driven) eating by blocking opioid-mediated food reward.

Research Applications

• Hypothalamic melanocortin system and POMC neuron research
• Opioid-dopamine reward pathway interaction studies
• Hedonic vs homeostatic appetite regulation investigation
• Combination pharmacology and synergistic mechanism research
• Food reward and craving neuroscience models